Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Summary

To evaluate the efficacy of KHK7791 in combination with phosphate binders by comparing changes in serum phosphorus levels between hemodialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 30 mg in combination with phosphate binders for 6 weeks and those receiving placebo in combination with phosphate binders.

Timeline

Start

2021-03-15

Primary completion

2021-09-27

Completion

2021-09-27

Drugs

Indications